Sterile drug product fill-finish is where years of development either pay off or unravel. Partnering with a CDMO that has isolator lines does not guarantee success. The difference lies in the depth of technical and operational expertise behind them.
This webinar will explore why disciplined commissioning and qualification of isolator-based aseptic operations is fundamental to reducing risk before the first batch, how manufacturing strategies hold up against evolving global regulatory standards and what it takes to protect high-value drug products throughout filling.
The featured speaker will address the operational factors that influence product loss and batch yield during fill-finish. By considering quality systems, isolator operations and manufacturing practices together, attendees will gain insight into approaches designed to protect valuable drug product and maximize the amount of each batch available for patient supply.
Register for this webinar to learn how effective fill-finish operations can align quality systems with GMP operational excellence, reduce product loss and convert more of every batch into supply for patients.
Who Should Attend
This webinar will appeal to professionals across biotech and pharmaceutical companies, including:
Manufacturing and Operations professionals
Process Development Scientists
Quality Assurance professionals
Emerging biotech companies
Mid- to large-size pharmaceutical companies
What You Will Learn
Attendees will gain insight into:
The importance of robust commissioning and qualification on an isolator line to de-risk the fill-finish process
Manufacturing strategies to support compliance with global regulatory standards such as Annex 1
How to minimize product loss and maximize batch yields
Register free on Xtalks:
https://xtalks.com/webinars/fill-finish-success-from-isolator-qualification-to-gmp-production/
